Article

PARP1 inhibition regulates tumor progression through modulation of RhoGDIα and vimentin in triple negative breast cancer

2026-07-20

Abstract excerpt

<h4>Background and Purpose</h4> PARP inhibitors have been evaluated in clinical trials for several cancers and Olaparib is FDA approved for treating BRCA deficient ovarian cancer. Numerous reports have suggested Poly(ADP-ribose) polymerase1(PARP1) overexpression in a variety of cancers including breast carcinomas and proposed the role of PARP1 in metastasis. However, the mechanism of PARP1 in regulating metastati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9361cd94-c66f-52b0-a5a9-97bdb6a1207b
DOI: 10.64898/2026.07.18.739208

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PARP1 inhibition regulates tumor progression through modulation of RhoGDIα and vimentin in triple negative breast cancerDOI 10.64898/2026.07.18.739208Read

PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG CellsSemantic proximity Read

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic DrugsSemantic proximity Read

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future PerspectivesSemantic proximity Read

Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity Read

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, TalazoparibSemantic proximity Read

PARP-1 as a novel target in endocrine-resistant breast cancerSemantic proximity Read

Highly Expressed PARP1 in Tumor Cells at the Invasive Tumor Front Was a Prognostic Biomarker for Oral Squamous Cell CarcinomaSemantic proximity Read

The Multifactorial Role of PARP-1 in Tumor MicroenvironmentSemantic proximity Read

Olaparib Combined with DDR Inhibitors Effectively Prevents EMT and Affects miRNA Regulation in TP53-Mutated Epithelial Ovarian Cancer Cell LinesSemantic proximity Read

Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatmentSemantic proximity Read

Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitorSemantic proximity Read

The Study on the Expression Level of PARP-1 in Glioma and Computational Screening of PARP-1 InhibitorsSemantic proximity Read